| Article Access Statistics | | | Viewed | 3169 | | | Printed | 92 | | | Emailed | 1 | | | PDF Downloaded | 454 | | | Comments | [Add] | | | Cited by others | 6 | | |
|
Click on image for details.
|
|
| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 52
| Issue : 6 | Page : 56-60 |
Computed tomography-guided percutaneous microwave ablation of patients 75 years of age and older with early-stage nonsmall cell lung cancer
X Han, X Yang, X Ye, Q Liu, G Huang, J Wang, W Li, A Zheng, Y Ni, M Men
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China
Correspondence Address:
X Ye
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.172514
Background: We aimed to assess the clinical outcome of computed tomography (CT)-guided percutaneous microwave ablation (MWA) in patients 75 years of age and older with early stage peripheral nonsmall cell lung cancer (NSCLC). Materials and Methods: Twenty-eight patients, aged ≥75 years, with Stage I and lymph node-negative IIa peripheral NSCLC underwent CT-guided percutaneous MWA in our hospital between July 2007 and March 2015. The overall 1-, 2-, 3-, and 4-year survival rates were estimated using Kaplan–Meier analysis. Adverse events were recorded. Results: The median follow-up time was 22.5 months. The overall median survival time (MST) was 35 months (95% confidence interval [CI] 22.3–47.7 months), and the cancer-specific MST was 41.9 months (95% CI 38.8–49.9 months). The 1-, 2-, 3-, and 4-year overall survival rates were 91.7%, 76.5%, 47.9%, and 47.9%, while the cancer-specific survival rates were 94.7%, 73.9%, 64.7%, and 64.7%, respectively. Median time to local progression was 28.0 months (95% CI 17.7–38.3 months). Major complications were included pneumothorax (21.4%, requiring drainage), pleural effusions (3.6%, requiring drainage), and pulmonary infection (3.6%). Conclusions: CT-guided percutaneous MWA is safe and effective for the treatment of patients 75 years of age and older with medically inoperable early stage peripheral NSCLC.
[FULL TEXT] [PDF]*
|
